Screening and early disease detection
Early detection
We are committed to supporting healthcare systems in improving screening and early disease detection through innovative digital solutions.
Innovative solutions for early disease detection are needed more than ever
The growing shortage of healthcare professionals, financial constraints and rising cases of chronic conditions highlight the limits of traditional methods.1,2 Early detection is vital to addressing the rise in non-communicable diseases (NCDs), yet screening and early disease detection programs face challenges like limited accessibility and low patient adherence, making it essential to innovate and improve these efforts.
Key challenges confronting healthcare systems
Burden of NCDs: Around 41 million people die each year from noncommunicable diseases, which is equivalent to 74% of all deaths globally1
Workforce shortage: 10 million healthcare worker shortage by 20302
Lack of physician time: 14.1 hours/day required from primary care providers (PCPs) to provide preventive care recommended by US guideline3
Low adherence to screening programs: Fewer than 70% of individuals aged 50–75 are taking part in colorectal cancer screening in the US4
We address these challenges with innovative digital solutions.
AI-powered decision support
Leverage AI to empower clinicians with accurate and timely decision-making tools.
Expanding screening accessibility
Digital platforms ensure broader access to screening, reaching more patients effectively.
Faster disease detection
Accelerate diagnosis with algorithms enabling early disease detection and timely interventions.
Increased healthcare efficiency
Streamline processes to improve resource management and reduce system costs.
See how digital solutions help enhance screening and early detection
Digital solutions and AI technology address today’s healthcare challenges by empowering clinicians to make informed decisions and deliver effective patient care. Innovative digital solutions can also play a pivotal role in nationwide screening programs, helping program managers gain greater transparency. At Roche, we are committed to equipping healthcare systems and professionals with the right tools. Learn more below about examples of navify solutions impacting patient care today.
Supporting cervical cancer screening
Explore how navify Cervical Screening supports screening through advanced digital tools. A detailed health and economic impact model highlights the benefits of improved adherence to screening guidelines, including reduced healthcare costs, streamlined workflows and enhanced patient engagement. Learn how adopting navify Cervical Screening can help reduce the global burden of cervical cancer and support the WHO’s elimination goals.5
- World Health Organization. Noncommunicable diseases [Internet; cited 2023 Sep 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
- World Health Organization. Health workforce [Internet; cited 2024 Nov 25]. Available from: https://www.who.int/health-topics/health-workforce#tab=tab_1
- Linzer M, Bitton A, Tu S-P, Plews-Ogan M, Durso SC. Key results for primary care physicians on time use for documentation and inbox management [Internet; cited 2022 Jul 1]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9848034/#:~:text=Key%20Results,for%20documentation%20and%20inbox%20management
- American Cancer Society National Colorectal Cancer Roundtable, American Cancer Society, Centers for Disease Control and Prevention. Colorectal cancer is a major public health problem [Internet]. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2012, 2014, 2016, 2018, 2020. National Screening Rate – BRFSS. Available from: https://nccrt.org/our-impact/data-and-progress/. [Accessed 2024 Nov 28].
- Optimizing cervical screening: Insights from a clinical simulation study in Brazil. MC--15103.
- Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.
- Individual case results may vary, and testimonials are not claimed to represent typical results. All testimonials are real participants and may not reflect the typical purchaser’s experience and are not intended to represent or guarantee that anyone will achieve the same or similar results. Please consider that the results shown here are based on the clinical simulation.
- MC--15660